Adherence to Lamivudine After an Early Withdrawal of an Important Role in the Long-Term Prevention of Hep

Transplantation 84, 650-654 DOI: 10.1097/01.tp.0000277289.23677.0a

Citation Report

#	Article	IF	CITATIONS
2	Liver transplantation for hepatitis B: What is the best hepatitis B immune globulin/antiviral regimen?. Liver Transplantation, 2008, 14, S15-S22.	1.3	37
3	A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology, 2008, 48, 1460-1466.	3.6	149
4	Liver transplantation in viral hepatitis: Prevention of recurrence. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 1153-1169.	1.0	16
6	Adherence to Lamivudine After an Early Withdrawal of Hepatitis B Immune Globulin Plays an Important Role in the Long-Term Prevention of Hepatitis B Virus Recurrence. Yearbook of Gastroenterology, 2008, 2008, 284-285.	0.1	0
7	Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World Journal of Gastroenterology, 2009, 15, 2489.	1.4	23
8	Special populations with hepatitis B virus infection. Hepatology, 2009, 49, S146-S155.	3.6	40
9	Hepatitis B virus cellular immunity after liver transplantation: A role in preventing hepatitis B virus recurrence?. Liver Transplantation, 2009, 15, 269-272.	1.3	0
10	Hepatitis B and liver transplantation: 2008 update. Reviews in Medical Virology, 2009, 19, 7-29.	3.9	20
11	Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transplant International, 2009, 22, 387-394.	0.8	63
12	Current management of hepatitis B virus infection before and after liver transplantation. Liver International, 2009, 29, 1294-1305.	1.9	65
13	Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transplantation, 2009, 15, 413-420.	1.3	29
14	The option of liver transplantation for hepatitis B: Where are we?. Digestive and Liver Disease, 2009, 41, S185-S189.	0.4	13
15	Liver transplantation for hepatitis B virus. Pre-emptive and peri-operative prophylaxis. Digestive and Liver Disease, 2009, 41, S191-S194.	0.4	3
16	The prevention of viral recurrence in the long term. Digestive and Liver Disease, 2009, 41, S195-S197.	0.4	11
17	Prevention of HBV recurrence after liver transplant: The role of combination therapy. Digestive and Liver Disease Supplements, 2009, 3, 98-103.	0.2	0
18	Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Current Opinion in Organ Transplantation, 2009, 14, 225-230.	0.8	20
19	Nucleoside Analogue Therapy Following One-Year Course of Hepatitis B Immunoglobulin in Preventing Hepatitis B Virus Reactivation after Living Donor Liver Transplantation. Tohoku Journal of Experimental Medicine, 2010, 222, 275-279.	0.5	6
21	Hepatitis B immunoglobulin immunoprophylaxis for hepatitis B: High, low, or no dose?1. Liver Transplantation, 2010, 16, S36-S39.	1.3	4

#	Article	IF	CITATIONS
22	Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transplant Infectious Disease, 2010, 12, 292-308.	0.7	89
23	Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. The Cochrane Library, 2010, , CD006005.	1.5	15
24	Viral load predicts HBV recurrence after liver transplant. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 657-658.	8.2	1
25	Current Status of Liver Transplantation for Hepatitis B Virus. Clinics in Liver Disease, 2011, 15, 753-764.	1.0	14
26	Passive Immunization. Primary Care - Clinics in Office Practice, 2011, 38, 681-691.	0.7	8
27	Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. Journal of Hepatology, 2011, 55, 587-593.	1.8	78
28	Individualizing hepatitis B infection prophylaxis in liver transplant recipients. Journal of Hepatology, 2011, 55, 507-509.	1.8	20
29	Antiâ€hepatitis B surface immunoglobulin reduction in early postoperative period after liver transplantation in hepatitis B virusâ€positive patients. Hepatology Research, 2011, 41, 1189-1198.	1.8	4
30	Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues?. Annals of Hepatology, 2011, 10, 180-187.	0.6	19
31	Management of chronic hepatitis B. European Journal of Gastroenterology and Hepatology, 2011, 23, 642-650.	0.8	13
32	Longâ€ŧerm outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation. Clinical Transplantation, 2011, 25, 517-522.	0.8	15
33	Prevention of lamivudineâ€resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only. Transplant Infectious Disease, 2011, 13, 299-302.	0.7	12
34	Posttransplantation Hepatitis B Prophylaxis with Combination Oral Nucleoside and Nucleotide Analog Therapy. American Journal of Transplantation, 2011, 11, 511-517.	2.6	70
35	Hepatitis B and Liver Transplantation: Update in Management before and after Transplantation. Current Hepatitis Reports, 2011, 10, 255-261.	0.3	0
36	Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: A systematic review. Liver Transplantation, 2011, 17, 1176-1190.	1.3	105
39	Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver International, 2012, 32, 1138-1145.	1.9	57
40	The option of HBIG-free prophylaxis against recurrent HBV. Journal of Hepatology, 2012, 56, 1189-1197.	1.8	75
41	The longâ€term efficacy of nucleos(t)ide analog plus a year of lowâ€dose <scp>HBIG</scp> to prevent <scp>HBV</scp> recurrence postâ€liver transplantation. Clinical Transplantation, 2012, 26, E561-9.	0.8	18

CITATION REPORT

#	Article	IF	Citations
π 43	Chronic Hepatitis B Infection. Clinics in Liver Disease, 2012, 16, 347-369.	1.0	54
43	Chronic nepatitis 5 infection. Chinics in Liver Disease, 2012, 10, 347-309.	1.0	54
44	Prevention of recurrent hepatitis B infection after liver transplantation. Hepatobiliary and Pancreatic Diseases International, 2013, 12, 465-472.	0.6	11
45	Hepatitis B virus: Prevention of recurrent infection. Clinical Liver Disease, 2013, 2, 169-172.	1.0	0
46	Treatment of Patients with HBV-related Decompensated Cirrhosis and Liver Transplanted Patients. Clinics in Liver Disease, 2013, 17, 451-473.	1.0	14
47	Excellent Liver Transplantation Survival and Prevention of Hepatitis B Recurrence Using Hepatitis B Immunoglobulin and Nucleoside or Nucleotide Analogue Along With Treating Physician Adherence to Treatment Protocol. Transplantation Proceedings, 2013, 45, 1188-1192.	0.3	1
48	High Genetic Barrier Nucleos(t)ide Analogue(s) for Prophylaxis From Hepatitis B Virus Recurrence After Liver Transplantation: A Systematic Review. American Journal of Transplantation, 2013, 13, 353-362.	2.6	128
49	Prophylaxis of hepatitis B infection in solid organ transplant recipients. Therapeutic Advances in Gastroenterology, 2013, 6, 309-319.	1.4	14
50	Hepatitis B and C in liver transplantation: new strategies to combat the enemies. Reviews in Medical Virology, 2013, 23, 172-193.	3.9	9
51	ls Hepatitis B Immunoglobulin Necessary in Prophylaxis of Hepatitis B Recurrence after Liver Transplantation? A Meta-Analysis. PLoS ONE, 2014, 9, e104480.	1.1	38
52	HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. International Reviews of Immunology, 2014, 35, 1-13.	1.5	12
53	Prevention of Hepatitis B Virus Reinfection in Liver Transplant Recipients. Intervirology, 2014, 57, 196-201.	1.2	21
54	Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation. Transplantation, 2015, 99, 1321-1334.	0.5	50
55	Recent advances in prevention of hepatitis B recurrence after liver transplantation. World Journal of Gastroenterology, 2015, 21, 829.	1.4	12
56	Hepatitis B virus quasispecies evolution after liver transplantation in patients under longâ€ŧerm lamivudine prophylaxis with or without hepatitis B immune globulin. Transplant Infectious Disease, 2015, 17, 208-220.	0.7	9
57	Prevention of Post-transplant HBV. Current Hepatology Reports, 2015, 14, 153-163.	0.4	0
58	Efficacy and effectiveness of anti-HBV therapy with early withdrawal of HBIG prophylaxis to prevent HBV recurrence following liver transplantation. Expert Opinion on Biological Therapy, 2015, 15, 665-677.	1.4	6
59	Transplantation for Hepatitis A and B. , 2015, , 105-119.		0
60	KASL clinical practice guidelines: management of chronic hepatitis B. Clinical and Molecular Hepatology, 2016, 22, 18-75.	4.5	155

CITATION REPORT

CITATION REPORT

#	Article	IF	CITATIONS
61	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology International, 2016, 10, 1-98.	1.9	1,908
62	Is hepatitis B immune globulin still needed after liver transplantation for chronic hepatitis B?. Hepatology, 2017, 66, 1023-1025.	3.6	5
63	Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation. Liver International, 2018, 38, 1940-1950.	1.9	15
65	Antiviral Therapy for AECHB and Severe Hepatitis B (Liver Failure). , 2019, , 371-455.		0
66	Taiwan consensus statement on the management of chronic hepatitis B. Journal of the Formosan Medical Association, 2019, 118, 7-38.	0.8	64
67	Documento de consenso de la Asociación Española para el Estudio del HÃgado sobre el tratamiento de la infección por el virus de la hepatitis B (2020). GastroenterologÃa Y HepatologÃa, 2020, 43, 559-587.	0.2	18
68	Review article: preventing hepatitis B graft infection in hepatitis B patients after liver transplantation: immunoglobulin vs antiâ€virals. Alimentary Pharmacology and Therapeutics, 2020, 52, 944-954.	1.9	4
69	Profilaxis y tratamiento de la infección por virus de la hepatitis B en el trasplante hepático. VII Documento de consenso de la Sociedad Española de Trasplante Hepático. GastroenterologÃa Y HepatologÃa, 2020, 43, 169-177.	0.2	2
70	Prophylaxis and treatment in liver transplantation. VII Consensus Document of the Spanish Society of Liver Transplantation. GastroenterologAa Y HepatologAa (English Edition), 2020, 43, 169-177.	0.0	0
72	Immunoglobulin, nucleos(t)ide analogues and hepatitis B virus recurrence after liver transplant: A metaâ€analysis. European Journal of Clinical Investigation, 2021, 51, e13575.	1.7	11
73	2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virusâ€related infection before and after liver transplantation. Alimentary Pharmacology and Therapeutics, 2021, 54, 583-605.	1.9	27
74	Asociación Mexicana de HepatologÃa A.C. Clinical guideline on hepatitis B. Revista De GastroenterologÃa De México (English Edition), 2021, 86, 403-432.	0.1	0
78	Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation. Journal of Clinical and Translational Hepatology, 2016, 4, 54-65.	0.7	25
79	KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clinical and Molecular Hepatology, 2012, 18, 109.	4.5	143
80	Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World Journal of Gastroenterology, 2013, 19, 9189.	1.4	25
81	Management of hepatitis B virus infection after liver transplantation. World Journal of Gastroenterology, 2015, 21, 12083.	1.4	15
82	Application of nucleoside analogues to liver transplant recipients with hepatitis B. World Journal of Gastroenterology, 2015, 21, 12091.	1.4	9
83	Prophylaxis and treatment of hepatitis B infection in the setting of liver transplantation. Revista Espanola De Enfermedades Digestivas, 2011, 103, 142-9.	0.1	3

	CHAILON	CHATION REPORT		
щ		IF	Citations	
#	Article	IF	CITATIONS	
84	Baseline Quantitative Hepatitis B Core Antibody Titer Is a Predictor for Hepatitis B Virus Infection Recurrence After Orthotopic Liver Transplantation. Frontiers in Immunology, 2021, 12, 710528.	2.2	4	
85	Antiviral therapy for hepatitis B virus-associated hepatic failure. , 2009, , 164-175.		3	
88	Hepatitis B Recurrence: Major Milestones and Current Status. , 2016, , 13-34.		0	
89	Organ Transplantation in HBV-Infected Patients. Molecular and Translational Medicine, 2016, , 361-397.	0.4	0	
90	Recurrent Primary Disease After Liver Transplantation. , 2018, , 784-815.e14.		0	
91	Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). GastroenterologÃa Y HepatologÃa (English Edition), 2020, 43, 559-587.	0.0	20	
92	Network meta-analysis on prophylactic regimens against recurrent hepatitis B virus infection after liver transplantation. Hepatobiliary Surgery and Nutrition, 2013, 2, 297-303.	0.7	3	
94	Evidence of Residual Ongoing Viral Replication in Chronic Hepatitis B Patients Successfully Treated with Nucleos(t)ide Analogues. Journal of Infectious Diseases, 0, , .	1.9	3	

TION REDO